Are generalist investors good or bad for biotech?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning! Today, we see Ginkgo pivot into AI, becoming yet another contender in a crowded market. Also, we see more documents destroyed at an Indian drug manufacturing plant, and offer up a fabulous podcast.

The need-to-know this morning

• Apellis Pharmaceuticals said its eye drug Syfovre was rejected for a second time by advisers to the European Medicines Agency.

Under pressure, Ginkgo Bioworks bets on AI

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the struggling company has now turned to AI-driven protein modeling and data generation amid layoffs and a plummeting stock price. Ginkgo will offer customers a new AI model to use for biological research, and a data service with vast datasets to help customers train their own models.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In